Related Experiment Videos
New immunotherapeutic strategies to control vaginal candidiasis
Walter Magliani1, Stefania Conti, Antonio Cassone
1Microbiology Section, Dept of Pathology and Laboratory Medicine, University of Parma, Viale Gramsci 14, 43100 Parma, Italy. magliwal@unipr.it
Abstract:
The widespread occurrence of mucosal infections caused by Candida, in particular recurrent vulvovaginal candidiasis among fertile-age women, together with the paucity of safe candidacidal antimycotics, have prompted a great number of investigations into the immunotherapy of candidal vaginitis. This article will discuss three different experimental approaches demonstrated to be potentially transferable to human disease: (1) the use of antibodies against well-defined cell-surface adhesins or enzymes; (2) the generation of yeast killer-toxin-like candidacidal anti-idiotypic antibodies and their engineered molecular derivatives (e.g. single chains, peptides); and (3) the generation of therapeutic vaccines and immunomodulators.
Insights
Investigating immunotherapy for Candida vaginitis is crucial due to frequent infections and limited safe treatments. This review explores antibody-based therapies, anti-idiotypic antibodies, and vaccines for treating yeast infections.
Area of Science:
- Immunology
- Mycology
- Infectious Diseases
Background:
- Recurrent vulvovaginal candidiasis is a common mucosal infection affecting women of reproductive age.
- There is a significant need for safe and effective candidacidal antimycotics.
- Immunotherapy is being explored as a promising alternative for treating candidal vaginitis.
Purpose of the Study:
- To review experimental immunotherapy approaches for candidal vaginitis.
- To discuss strategies potentially transferable to human treatment.
- To highlight advancements in antibody-based and vaccine-based immunotherapies.
Main Methods:
- Review of experimental approaches for immunotherapy of candidal vaginitis.
- Discussion of antibody-based strategies targeting Candida cell-surface adhesins or enzymes.
- Exploration of anti-idiotypic antibodies and their derivatives (single chains, peptides) mimicking yeast killer toxins.
- Examination of therapeutic vaccines and immunomodulators for Candida infections.
Main Results:
- Three distinct experimental immunotherapy approaches show potential for human application.
- Antibody-based therapies targeting specific Candida components are under investigation.
- Engineered anti-idiotypic antibodies and novel vaccine strategies are being developed.
Conclusions:
- Immunotherapy offers a promising avenue for managing Candida vaginitis, addressing the limitations of conventional antimycotics.
- Further research into antibody-based treatments, anti-idiotypic antibodies, and vaccines is warranted.
- These innovative approaches hold potential for safe and effective treatment of recurrent yeast infections.